Raices M

Language: English
References: 6
Page: 168-169
PDF size: 233.02 Kb.

Text Extraction

Here we show the points of view of Julio Cesar Aguilar PhD, who kindly accepted to share with us his considerations on the current development of therapeutics against hepatitis B. He is the scientific leader of the NASVAC vaccine project at the Vaccine Department, in the Center for Genetic Engineering and Biotechnology (CIGB) of Havana, Cuba.

REFERENCES

1. Wasley A, Grytdal S, Gallagher K; Centers for Disease Control and Prevention (CDC). Surveillance for acute viral hepatitis--United States, 2006. MMWR Surveill Summ. 2008;57(2):1-24.

2. Zuckerman JN. Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines. J Med Virol. 2006;78:169-77.

3. Jafri SM, Lok AS. Antiviral therapy for chronic hepatitis B. Clin Liver Dis. 2010;14(3):425-38.

4. Lampertico P, Vigano M, Manenti E et al. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology. 2005;42:1414-9.

5. Vandepapelière P, Lau GK, Leroux-Roels G, Horsmans Y, Gane E, Tawandee T, Merican MI, Win KM, Trepo C, Cooksley G, Wettendorff M, Ferrari C; Therapeutic HBV Vaccine Group of Investigators. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine. 2007;25:8585-97.

6. Hui CK, Lau GKK. Advances in immunomodulating therapy of HBV infection. Int J Med Sci. 2005;2:24-29.